New Hope for Allergy Sufferers
Interview with Dr. Flora Beiche-Scholz, Managing Director of ALK-Abelló Arzneimittel GmbH
More than 500 million people around the world suffer from allergies, and this number is on the rise. While seasonal pollen allergies are rarely life-threatening, they significantly diminish the quality of life for sufferers. More severe allergies, such as nut allergies, can lead to anapyhlactic shock. This is something that Dr. Flora Beiche-Scholz, Managing Director of ALK-Abelló Arzneimittel GmbH knows only too well. As someone with a severe pine nut allergy, she is even more invested than most in the search for effective treatments. In an interview with European Business, Dr. Beiche Scholz describes how Danish company ALK-Abelló’s approach promises hope of relief to the growing number of allergy sufferers worldwide.
European Business: Dr. Beiche-Scholz, how does ALK-Abelló aim to address the challenges posed by allergies?
Dr. Flora Beiche-Scholz: At ALK-Abelló, our goal for the past 100 years has been to help people with allergies. We focus on treating the root causes of allergies rather than just alleviating symptoms. Our approach involves immunotherapy, which helps the body develop tolerance to allergens. This is crucial because although allergies have become a true epidemic, only a small fraction of allergy sufferers receive adequate treatment.
European Business: Can you explain the innovative therapies that ALK-Abelló offers?
Dr. Flora Beiche-Scholz: We offer sublingual tablets, which represent a significant advancement in the treatment of allergies. Unlike traditional allergy treatments that often involve injections, sublingual tablets allow patients to take their medication conveniently at home. This therapy works by placing the tablet under the tongue, where it dissolves almost instantaneously and allows the allergens to be absorbed directly into the bloodstream. Sublingual immunotherapy has been shown to be effective for various allergens, including pollen, and house dust mites. The transition to this form of treatment has made it possible for patients to take control of their allergy management in a way that fits seamlessly into their daily lives.
European Business: How has this therapy been developed further?
Dr. Flora Beiche-Scholz: Since the introduction of our first sublingual immunotherapy tablet (SLIT) in 2006, we have continued to expand our product line, developing new formulations targeting different allergens. This innovation not only improves patient adherence to treatment but also opens up new markets for us, allowing us to reach more allergy sufferers who can benefit from our therapies. Overall, we believe that sublingual tablets offer a promising and patient-friendly option for those seeking relief from their allergies. This was most recently confirmed by the recent approval by the National Institute for Health and Care Excellence (NICE) in the UK of our house dust mite sublingual immunotherapy-tablet for the treatment of persistent moderate to severe allergic rhinitis caused by house dust mites in adults and adolescents. Furthermore, we recently received the approval by health authorities in 21 EU countries to treat allergies in young children aged 5 to 11 with our house dust mite SLIT treatment. This endorsement not only validates our efforts but also confirms the effectiveness of our products on an international level.
European Business: How important is societal acceptance of allergy treatments?
Dr. Flora Beiche-Scholz: It is crucial. Many people with allergies do not view themselves as patients and are often unaware of the treatment options available to them. Often, they perceive their allergies as mere inconveniences rather than serious health issues. Therefore, we need to invest in public education as much as we invest in product development.
European Business: How does ALK-Abelló address the gap in awareness and education?
Dr. Flora Beiche-Scholz: We work to raise awareness through various channels, including informational campaigns, partnerships with healthcare professionals, and participation in allergy-related events and conferences. Our goal is to empower patients to seek appropriate medical advice and treatment sooner rather than later. Furthermore, we provide resources and training for healthcare providers to ensure they are well-informed about the latest advancements in allergy treatments, including our allergy-immunotherapy options. By equipping them with the necessary knowledge, we aim to improve the referral process for patients who may benefit from our therapies.
European Business: What challenges does ALK-Abelló face in the current market?
Dr. Flora Beiche-Scholz: Despite our advancements, we still face challenges, particularly the increasing prevalence of allergic diseases. Factors such as air pollution and climate change contribute to this rise, necessitating ongoing research and development. We need to find innovative solutions to improve patient care while addressing the underlying causes of allergies.
European Business: How does digitalization play a role in ALK-Abelló’s strategy?
Dr. Flora Beiche-Scholz: Digitalization is extremely important for us. It offers great potential for enhancing patient education and improving internal efficiency. As demands on companies grow, having strong digital capabilities is essential for meeting these challenges effectively.
European Business: What is ALK-Abelló’s commitment to social responsibility?
Dr. Flora Beiche-Scholz: We are very aware of our social responsibility, particularly regarding gender representation in leadership roles. We strive to create a work environment that promotes diversity and equality of opportunity. Our high employee loyalty and stability reflect our positive corporate culture.
European Business: In summary, what is ALK-Abelló’s vision for the future of allergy treatment?
Dr. Flora Beiche-Scholz: Our vision is clear: we want to continue to be pioneers in allergy treatment while improving the quality of life for allergy sufferers. With a focus on research, education, and innovative therapeutic approaches, we aim to play a central role in the fight against allergies for many years to come.